Daniel Bjørklund Andersen

Daniel Bjørklund Andersen serves as a Postdoc in the Juul Holst Group at the Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, specializing in endocrinology and metabolism research within the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR).

Dr. Andersen's research centers on gut hormone systems, particularly the glucagon-like peptide-1 (GLP-1) receptor pathway and its implications for metabolic disorders. His work integrates molecular biology, transgenic animal models, and physiological measurements to investigate hormone signaling mechanisms. Key research areas include GLP-1 receptor expression mapping, cerebrospinal fluid regulation, natural peptide toxins affecting glucose homeostasis, and the regulation of glucagon secretion. His methodological approach combines advanced molecular techniques with in vivo physiological studies to elucidate fundamental mechanisms of metabolic regulation.

Analysis of his publication record reveals a consistent focus on GLP-1 receptor biology and related metabolic pathways, with significant contributions to understanding hormone-receptor interactions across multiple organ systems. His research demonstrates translational potential for diabetes and obesity therapeutics, particularly through studies of natural peptide systems and receptor modulation.

Dr. Andersen is an integral member of the Juul Holst Group at CBMR, collaborating with Professor Jens Juul Holst's renowned research team. The group operates within state-of-the-art facilities at the University of Copenhagen's Panum Institute, providing comprehensive resources for metabolic research from molecular to physiological levels.